Innate Pharma to Join Kempen Life Sciences Conference

Innate Pharma SA, a clinical-stage biotechnology firm, announced its participation at the Kempen Life Sciences Conference. Scheduled for April 15-16, 2026, in Amsterdam, this event will feature one-on-one meetings between Innate Pharma's executives and investors.

Specializing in cancer immunotherapies, Innate Pharma is advancing a range of innovative and potential first or best-in-class antibody therapeutics. These include the differentiated Nectin-4 ADC known as IPH4502, the lacutamab antibody, and monalizumab, developed in collaboration with AstraZeneca.

Innate Pharma is noted for its partnerships with notable biopharmaceutical companies like Sanofi and AstraZeneca. Based in Marseille, France, the company is publicly traded on Euronext Paris and Nasdaq under the ticker codes IPH and IPHA respectively.